SG149063A1 - Use of modified cyclosporins for the treatment of hcv disorders - Google Patents

Use of modified cyclosporins for the treatment of hcv disorders

Info

Publication number
SG149063A1
SG149063A1 SG200809555-6A SG2008095556A SG149063A1 SG 149063 A1 SG149063 A1 SG 149063A1 SG 2008095556 A SG2008095556 A SG 2008095556A SG 149063 A1 SG149063 A1 SG 149063A1
Authority
SG
Singapore
Prior art keywords
treatment
hcv
disorders
cyclosporins
modified
Prior art date
Application number
SG200809555-6A
Other languages
English (en)
Inventor
Makota Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG149063A1 publication Critical patent/SG149063A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG200809555-6A 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders SG149063A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
SG149063A1 true SG149063A1 (en) 2009-01-29

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200809555-6A SG149063A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Country Status (30)

Country Link
US (1) US7968518B2 (zh)
EP (2) EP1663287B1 (zh)
JP (1) JP4688806B2 (zh)
KR (1) KR101116968B1 (zh)
CN (1) CN1842343A (zh)
AU (2) AU2004268382A1 (zh)
BR (1) BRPI0414062B8 (zh)
CA (1) CA2537137C (zh)
CY (1) CY1110506T1 (zh)
DE (1) DE602004022061D1 (zh)
DK (1) DK1663287T3 (zh)
ES (1) ES2328361T3 (zh)
GB (1) GB0320638D0 (zh)
HK (1) HK1091732A1 (zh)
HR (1) HRP20090535T1 (zh)
IL (1) IL173909A (zh)
IS (1) IS2917B (zh)
MA (1) MA28032A1 (zh)
MX (1) MXPA06002394A (zh)
NO (1) NO20061479L (zh)
NZ (1) NZ545495A (zh)
PL (1) PL1663287T3 (zh)
PT (1) PT1663287E (zh)
RU (1) RU2389501C2 (zh)
SG (1) SG149063A1 (zh)
SI (1) SI1663287T1 (zh)
TN (1) TNSN06071A1 (zh)
TW (1) TWI342782B (zh)
WO (1) WO2005021028A1 (zh)
ZA (1) ZA200601550B (zh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1091975B1 (fr) 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2573207C (en) * 2004-07-14 2013-04-16 Novartis Ag Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
SG139750A1 (en) 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
KR101309409B1 (ko) * 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
DE602005010607D1 (de) 2004-11-22 2008-12-04 Astellas Pharma Inc Zyklosporinanalog
KR20070089954A (ko) * 2004-12-23 2007-09-04 노파르티스 아게 플라비비리대 치료용 화합물
NZ555143A (en) 2004-12-23 2009-12-24 Novartis Ag Compositions for HCV treatment
AU2006259348B2 (en) 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
NZ567262A (en) * 2005-09-30 2011-12-22 Scynexis Inc Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection
US7872097B2 (en) * 2005-10-26 2011-01-18 Astellas Pharma Inc. Cyclic peptide compounds
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
WO2008043797A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CA2674296C (en) * 2007-01-04 2015-11-24 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
MX2009011512A (es) * 2007-05-02 2009-11-12 Astellas Pharma Inc Nuevos compuestos peptidos ciclicos.
JPWO2009028418A1 (ja) * 2007-08-24 2010-12-02 北海道公立大学法人 札幌医科大学 シクロスポリンａ結合タンパク質
WO2010002428A2 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2307446A4 (en) * 2008-07-30 2012-11-07 Isotechnika Pharma Inc NON-IMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGOUS MOLECULES
WO2010035722A1 (ja) * 2008-09-24 2010-04-01 アステラス製薬株式会社 ペプチド化合物およびその製造方法
BRPI0920502A2 (pt) * 2008-11-06 2015-12-22 Debio Rech Pharma Sa compostos cicloundecadepsipeptídeos e seu uso como medicamento
JP5780969B2 (ja) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
WO2010088573A1 (en) * 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
JP6110791B2 (ja) 2010-11-30 2017-04-05 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
RU2630690C9 (ru) 2010-12-15 2017-12-28 КонтраВир Фармасьютикалз, Инк. МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
JP2014509628A (ja) 2011-03-31 2014-04-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
PL2694087T3 (pl) 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
SG193908A1 (en) 2011-04-13 2013-11-29 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
EP2760461A1 (en) 2011-09-27 2014-08-06 Novartis AG Alisporivr for treatment of hepatis c virus infection
CN104284671A (zh) 2012-05-07 2015-01-14 诺华股份有限公司 使用阿拉泊韦的药代动力学调节
CN104487449A (zh) 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
JP2016538317A (ja) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎を防止または治療するための新規シクロスポリン類似体
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ500713A (en) 1997-04-04 2000-07-28 Yoshitomi Pharmaceutical 2-aminopropane-1,3-diol compounds and medicinal use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
EP1091975B1 (fr) * 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
CA2415678A1 (en) 2000-07-13 2003-01-10 Sankyo Company Limited Amino alcohol derivatives
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1372695A2 (en) * 2000-10-19 2004-01-02 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
SG139750A1 (en) 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
NZ555143A (en) 2004-12-23 2009-12-24 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
US7968518B2 (en) 2011-06-28
BRPI0414062B8 (pt) 2021-05-25
EP1797892A1 (en) 2007-06-20
MXPA06002394A (es) 2006-06-20
IS8371A (is) 2006-03-24
US20070275884A1 (en) 2007-11-29
ES2328361T3 (es) 2009-11-12
IL173909A0 (en) 2006-07-05
JP4688806B2 (ja) 2011-05-25
RU2006110533A (ru) 2007-10-10
MA28032A1 (fr) 2006-07-03
NZ545495A (en) 2010-01-29
DK1663287T3 (da) 2009-11-09
HRP20090535T1 (hr) 2009-11-30
CN1842343A (zh) 2006-10-04
HK1091732A1 (en) 2007-01-26
ZA200601550B (en) 2007-05-30
DE602004022061D1 (de) 2009-08-27
BRPI0414062A (pt) 2006-10-24
AU2008203031B2 (en) 2011-04-07
CY1110506T1 (el) 2015-04-29
IS2917B (is) 2014-12-15
SI1663287T1 (sl) 2009-10-31
CA2537137C (en) 2013-05-28
EP1663287A1 (en) 2006-06-07
PT1663287E (pt) 2009-09-03
KR20060132798A (ko) 2006-12-22
BRPI0414062B1 (pt) 2019-06-25
CA2537137A1 (en) 2005-03-10
JP2007504260A (ja) 2007-03-01
GB0320638D0 (en) 2003-10-01
TWI342782B (en) 2011-06-01
NO20061479L (no) 2006-06-02
PL1663287T3 (pl) 2009-12-31
TW200524626A (en) 2005-08-01
RU2389501C2 (ru) 2010-05-20
TNSN06071A1 (en) 2007-10-03
WO2005021028A1 (en) 2005-03-10
EP1797892B1 (en) 2013-10-23
IL173909A (en) 2011-03-31
AU2008203031A1 (en) 2008-07-31
KR101116968B1 (ko) 2012-03-14
AU2004268382A1 (en) 2005-03-10
EP1663287B1 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
PT1656346E (pt) Indole 1,2,3,4-tetrassubstituído para o tratamento de doenças respiratórias
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
MY135829A (en) Analeptic and drug combinations
AU2003298911A8 (en) Cyclosporins for the treatment of autoimmune diseases
TW200510398A (en) Novel compounds
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EP1436279A4 (en) CHEMICAL COMPOUNDS
GB0201025D0 (en) The treatment of degenerative diseases
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
ZA200407501B (en) "The treatment of sludge".
TW200500012A (en) Novel lactobacillus and use thereof